Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: ENMD-2076
Sponsor: CASI Pharmaceuticals, Inc.
Collaborators: University of Colorado, Denver|Indiana University Melvin and Bren Simon Cancer Center